Nexstim Plc supports 13th International Symposium on nTMS in Neurosurgery and Neuromodulation and showcases NBS 6 system for presurgical mapping

Press release, Helsinki, 7 October 2024 at 9:15 AM (EEST)

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") is again supporting the International Symposium on nTMS in Neurosurgery and Neuromodulation, which will be held on 11-12 October 2024 in Berlin, Germany. The event is organized by the neurosurgery departments of Charité Berlin, Heidelberg University Hospital and the Technical University of Munich.

The symposium attracts a wide international audience from Europe, US, and Asia and provides an update on navigated Transcranial Magnetic Stimulation (nTMS) for both therapy and brain mapping by leaders in their respective fields. Keynote lectures include prestigious clinicians and researchers from a variety of backgrounds. Among others, the audience will hear from:

• Joshua Brown, McLean Hospital, Harvard Medical School on current best practices and new perspectives for the treatment of depression with nTMS
• Stephanie E. Combs, TU Munich on function-guided radiotherapy
• Hugues Duffau, Montpellier University Medical Center on brain plasticity in neurosurgery
• Brian Edlow, Massachusetts General Hospital, Harvard Medical School on measuring consciousness in the intensive care unit with nTMS-EEG
• Stefanie Forkel, Radboud University Nijmegen on neurobiology of language - insights from neuroimaging
• Michael Fox, Harvard Medical School on connectivity-based target selection in brain stimulation
• Sebastian Ille, Heidelberg University Hospital on nTMS mapping of higher brain functions beyond standard language mapping
• Satu Jääskeläinen, Turku University Hospital on current best practice and new perspectives for the treatment of pain with nrTMS
• Sandro Krieg, Heidelberg University Hospital on nTMS for therapy of postsurgical paresis
• Bernhard Meyer, TU Munich on nTMS for individual functional mapping from risk assessment to surgical guidance
• Shalini Narayana, LeBonheur Children's Hospital on TMS language mapping in children
• Sujit Prabhu, MD Anderson Cancer Center on nTMS for preoperative planning with ECoG
• Kathleen Seidel, Inselspital Bern on Intraoperative cortico-cortical evoked potentials in brain tumor surgery-and possible implications in nTMS
• Mario Rosanova, University of Milan on how we can probe changes in cortical circuits with nTMS-EEG
• Anastasia Shulga, Helsinki University Hospital on motor rehabilitation after spinal cord injury
• Francesco Vergani, King's College London on TMS-tractography assessment of traumatic spinal cord injury patients: preliminary study

In addition to prestigious keynote lectures, many clinicians and researchers will be giving presentations, with oftentimes new and innovative approaches on how nTMS could be utilized in the future. The combination of longstanding experience, groundbreaking research and innovative ideas stimulates the discussion during the networking dinner hosted on Friday evening, laying ground for collaborative work across centers and paving ways for future research.

At the event, Nexstim will offer an exclusive preview of its upcoming product, NBS 6 for pre-procedural mapping, prior to its planned release in 2025. Long-time nTMS users and interested attendees will have the opportunity to explore the enhanced, modernized platform and exciting new features, providing valuable feedback and building anticipation for the launch.

The NBS 6 for pre-procedural mapping follows the previous release of the NBS 6 for therapy, continuing Nexstim's commitment to innovation and elevated user experience. The NBS 6 for presurgical mapping has not yet been approved by the FDA and does not yet hold a CE mark. The NBS 6 is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 is CE marked for the treatment of major depression and chronic neuropathic pain.

Mikko Karvinen, CEO, Nexstim Plc said: "We are pleased to support this symposium that has its place as an important meeting for the experts in the field of navigated brain stimulation. The symposium has repeatedly attracted a large international audience to discuss the latest developments in the field. This also clearly shows the growing international interest across physicians in the use of TMS in neurosurgery and in numerous therapy treatments."

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
[email protected]

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com

Public link

Please use the above public link if you want to share this noodl on another website.